Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: December Update

Performance overview
Value at beginning of month: $114,071.00
Value at end of month: $139,073.53
Month over month change: 15.38%
Total CAGR: 39.07%

Related indices, monthly change
NASDAQ: +0.81%
IVV (iShares Core S&P 500): +0.97%
IBB (iShares NASDAQ Biotechnology Index): +1.01%
MXI (iShares Global Materials): +3.71%
VEGI (iShares MSCI Global Agriculture Producers): +2.37%
ICLN (iShares Clean Energy): +5.42%

Individual performances


GenScript stole the show this December capping off a strong month with a $350 million licensing deal with Janssen, but two of the other large companies in the index, Codexis and Calyxt also had very strong months. Intrexon continued to lag, finishing out the month on a year-low closing price. 

Changes made to index

There are major changes happening in order to include therapeutic synthetic biology companies. Those changes are explained in the 2017 update post. 

You can view the index here.

Allocation as of December 29, 2017


Calvin Schmidt Synthetic Biology Index: 2017 Review

Synthetic biology venture investment in 2017